First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
Subscribe To Our Newsletter & Stay Updated
